Andy Karabajakian

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Esma Saâda-Bouzid, Cécile Defaucheux, Andy Karabajakian et al. · Annals of Oncology · 2017 · 609 citations

Medicine, Oncology, Pharmacotherapy +16

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

Manu Prasad, Jonathan Zorea, Sankar Jagadeeshan et al. · Journal for ImmunoTherapy of Cancer · 2022 · 69 citations · Full text

Medicine, Immunology, Oncology +17

Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and lung cancer patients

Jean‐Philippe Foy, Andy Karabajakian, Sandra Ortiz‐Cuaran et al. · European Journal of Cancer · 2022 · 66 citations

Life Sciences, Immunology, Oncology +17

Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity

Andy Karabajakian, Jebrane Bouaoud, Lucas Michon et al. · Oral Oncology · 2021 · 34 citations · Full text

Medicine, Oncology, Pathology +17

Molecular Mechanisms of Kaposi Sarcoma Development

Andy Karabajakian, Isabelle Ray‐Coquard, Jean‐Yves Blay · Cancers · 2022 · 29 citations · Full text

Life Sciences, Molecular Biology, Pathobiology +17